Brucker Alexander J
Department of Ophthalmology, Scheie Eye Institute, Philadelphia, Pennsylvania 19104, USA.
Retina. 2009 Jun;29(6 Suppl):S2-4. doi: 10.1097/IAE.0b013e3181ad255f.
Age-related macular degeneration (AMD) is a significant source of morbidity in aging adults. The damage to the macula and vision loss in advanced forms of wet AMD stems from choroidal neovascularization that originates in the choroid and proliferates through breaks in the Bruch membrane. Although inhibitors of angiogenesis have been a recent advance in the treatment of AMD associated with neovascularization, these agents do not appear to cure the condition. Rather, antiangiogensis agents halt or slow progression of AMD in most cases. The development of additional treatments to provide more effective disease control may depend on addressing several pathophysiologic processes simultaneously. The search for more effective treatments will require a better understanding of the different physiologic processes involved with this disease process.
年龄相关性黄斑变性(AMD)是老年人发病的一个重要原因。湿性AMD晚期黄斑受损及视力丧失源于脉络膜新生血管形成,其起源于脉络膜并通过布鲁赫膜的破损处增殖。尽管血管生成抑制剂是近期治疗与新生血管形成相关的AMD的一项进展,但这些药物似乎无法治愈该病。相反,抗血管生成药物在大多数情况下会阻止或减缓AMD的进展。开发更多能提供更有效疾病控制的治疗方法可能取决于同时解决几个病理生理过程。寻找更有效的治疗方法需要更好地了解与该疾病过程相关的不同生理过程。